These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 34321444)

  • 21. Real Life Egyptian Experience of Daclatasvir Plus Sofosbuvir with Ribavirin in Naïve Difficult to Treat HCV Patients.
    Wahsh EA; Hussein AK; Gomaa AA; Baraka MA; Al-Deen Abead M
    Infect Disord Drug Targets; 2020; 20(1):43-48. PubMed ID: 30009715
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness analysis of Daclatasvir/Sofosbuvir for the treatment of the HCV patients failed after the first line with second generation of DAAs in Italy.
    Ruggeri M; Rolli FR; Kondili LA; Drago C; De Solda F; Nappi C; Cicchetti A
    Expert Rev Pharmacoecon Outcomes Res; 2019 Jun; 19(3):363-374. PubMed ID: 30351994
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort.
    Welzel TM; Petersen J; Herzer K; Ferenci P; Gschwantler M; Wedemeyer H; Berg T; Spengler U; Weiland O; van der Valk M; Rockstroh J; Peck-Radosavljevic M; Zhao Y; Jimenez-Exposito MJ; Zeuzem S
    Gut; 2016 Nov; 65(11):1861-1870. PubMed ID: 27605539
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Peripheral Expression of
    Afzal M; Ali A; Sheikh N; Rafique S; Idrees M
    J Interferon Cytokine Res; 2020 Jun; 40(6):301-309. PubMed ID: 32486887
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C patients with genotype-2 infection after completed treatment.
    Cheng TS; Liang PC; Huang CF; Yeh ML; Huang CI; Lin ZY; Chen SC; Huang JF; Dai CY; Hsieh PH; Chuang WL; Yu ML
    Kaohsiung J Med Sci; 2021 Apr; 37(4):334-345. PubMed ID: 33151016
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sofosbuvir and daclatasvir for the treatment of COVID-19 outpatients: a double-blind, randomized controlled trial.
    Roozbeh F; Saeedi M; Alizadeh-Navaei R; Hedayatizadeh-Omran A; Merat S; Wentzel H; Levi J; Hill A; Shamshirian A
    J Antimicrob Chemother; 2021 Feb; 76(3):753-757. PubMed ID: 33338232
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Single- and multiple-ascending dose studies to evaluate the safety, tolerability, and pharmacokinetics of daclatasvir and asunaprevir in healthy male Japanese subjects.
    Shiozaki T; Ueno T; Nagashima H; Yamahira N; Hiraoka M; Eley T; Bifano M; Bertz RJ
    Int J Clin Pharmacol Ther; 2015 Apr; 53(4):292-302. PubMed ID: 25740262
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Viral kinetics analysis and virological characterization of treatment failures in patients with chronic hepatitis C treated with sofosbuvir and an NS5A inhibitor.
    Fourati S; Guedj J; Chevaliez S; Nguyen THT; Roudot-Thoraval F; Ruiz I; Soulier A; Scoazec G; Varaut A; Poiteau L; Francois M; Mallat A; Hézode C; Pawlotsky JM
    Aliment Pharmacol Ther; 2018 Mar; 47(5):665-673. PubMed ID: 29271114
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SVR 24 Achievement Two Weeks After a Tripled Dose of Daclatasvir in an HCV Genotype 3 Patient.
    Lo Menzo S; Biagi E; Di Nuzzo M; Grilli A; Contini C
    Ann Hepatol; 2018 July - August ,; 17(4):661-664. PubMed ID: 29893709
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Successful Anti-HCV Therapy of a Former Intravenous Drug User with Sofosbuvir and Daclatasvir in a Peritranspant Setting: A Case Report.
    Seifert LL; Heinzow H; Kabar I; Christensen S; Hüsing A; Schmidt HH
    Am J Case Rep; 2016 Aug; 17():605-10. PubMed ID: 27554644
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Single-pill sofosbuvir and daclatasvir for treating hepatis C in patients co-infected with human immunodeficiency virus.
    Dehghan Manshadi SA; Merat S; Mohraz M; Rasoolinejad M; Sali S; Mardani M; Tabarsi P; Somi MH; Sedghi R; Tayeri K; Nikbin M; Karimi J; Sharifi AH; Kalantari S; Norouzi A; Merat D; Malekzadeh Z; Mirminachi B; Poustchi H; Malekzadeh R
    Int J Clin Pract; 2021 Aug; 75(8):e14304. PubMed ID: 33930223
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Limitations of daclatasvir/asunaprevir plus beclabuvir treatment in cases of NS5A inhibitor treatment failure.
    Teraoka Y; Uchida T; Imamura M; Hiraga N; Osawa M; Kan H; Saito Y; Tsuge M; Abe-Chayama H; Hayes CN; Makokha GN; Aikata H; Miki D; Ochi H; Ishida Y; Tateno C; Chayama K
    J Gen Virol; 2018 Aug; 99(8):1058-1065. PubMed ID: 29916799
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and Safety of Simeprevir or Daclatasvir in Combination With Sofosbuvir for the Treatment of Hepatitis C Genotype 4 Infection.
    Babatin MA; Alghamdi AS; Albenmousa A; Alaseeri A; Aljarodi M; Albiladi H; Alsahafi A; Almugharbal M; Alothmani HS; Sanai FM; Bzeizi KI
    J Clin Gastroenterol; 2018; 52(5):452-457. PubMed ID: 28767462
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of chronic HCV infection with DAAs in Rio de Janeiro/Brazil: SVR rates and baseline resistance analyses in NS5A and NS5B genes.
    Costa VD; Brandão-Mello CE; Nunes EP; Dos Santos Silva PGC; de Souza Rodrigues LLLX; Lampe E; do Amaral Mello FC
    PLoS One; 2019; 14(5):e0216327. PubMed ID: 31063475
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and efficacy of combined sofosbuvir/daclatasvir treatment of children and adolescents with chronic hepatitis C Genotype 4.
    Abdel Ghaffar TY; El Naghi S; Abdel Gawad M; Helmy S; Abdel Ghaffar A; Yousef M; Moafy M
    J Viral Hepat; 2019 Feb; 26(2):263-270. PubMed ID: 30380158
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Single-dose pharmacokinetics and safety of daclatasvir in subjects with renal function impairment.
    Garimella T; Wang R; Luo WL; Hwang C; Sherman D; Kandoussi H; Marbury TC; Alcorn H; Bertz R; Bifano M
    Antivir Ther; 2015; 20(5):535-43. PubMed ID: 25654812
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real-World Efficacy of Daclatasvir and Sofosbuvir, With and Without Ribavirin, in HIV/HCV Coinfected Patients With Advanced Liver Disease in a French Early Access Cohort.
    Lacombe K; Fontaine H; Dhiver C; Metivier S; Rosenthal E; Antonini T; Valantin MA; Miailhes P; Harent S; Batisse D; Pageaux GP; Chas J; Aumaitre H; Dominguez S; Allegre T; Lafeuillade A; Billaud E; De Truchis P; Perre P; Leroy V; De Ledinghen V; Sogni P; Dabis F; Zhao Y; Filipovics A; Fedchuk L; Akremi R; Bennai Y; Salmon Ceron D
    J Acquir Immune Defic Syndr; 2017 May; 75(1):97-107. PubMed ID: 28272163
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Daclatasvir plus sofosbuvir, with or without ribavirin, is highly effective for all kinds of genotype-2 chronic hepatitis-C infection in Taiwan.
    Wu SH; Chu CJ; Su CW; Lin CC; Lee SD; Wang YJ; Lee FY; Huang YH; Hou MC
    J Chin Med Assoc; 2019 Sep; 82(9):693-698. PubMed ID: 31356562
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High sustained viral response rate in patients with hepatitis C using generic sofosbuvir and daclatasvir in Phnom Penh, Cambodia.
    Zhang M; O'Keefe D; Iwamoto M; Sann K; Kien A; Hang V; Brucker C; Jolivet P; Ly S; Chhit D; Balkan S; Marquardt T; Le Paih M; Dousset JP
    J Viral Hepat; 2020 Sep; 27(9):886-895. PubMed ID: 32358826
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sofosbuvir/daclatasvir regimens for the treatment of COVID-19: an individual patient data meta-analysis.
    Simmons B; Wentzel H; Mobarak S; Eslami G; Sadeghi A; Ali Asgari A; Abbaspour Kasgari H; Tirgar Fakheri H; Merat S; Hill A
    J Antimicrob Chemother; 2021 Jan; 76(2):286-291. PubMed ID: 33063117
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.